Literature DB >> 22729507

How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al.

Ulf Schönermarck, Simon Rau, Michael Fischereder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22729507     DOI： 10.1002/art.34590

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  2 in total

1.  Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.

Authors:  Dario Roccatello; Savino Sciascia; Stefano Murgia; Giacomo Quattrocchio; Michela Ferro; Emanuele De Simone; Carla Naretto; Antonella Barreca; Andrea Sammartino; Daniela Rossi; Roberta Fenoglio
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

2.  The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.

Authors:  Dario Roccatello; Savino Sciascia; Daniela Rossi; Mirella Alpa; Carla Naretto; Massimo Radin; Roberta Fenoglio; Simone Baldovino; Elisa Menegatti
Journal:  Oncotarget       Date:  2017-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.